Science has made great progress in the treatment of certain cancers with targeted and combination therapies, yet prolonged remissions or cures are rare because most cancer therapies only inhibit cell… ...

It is estimated that by 2020, over 450,000 Californians will suffer from vision loss or blindness due to the age-related macular degeneration (AMD), the most common cause of retinal degeneration… ...

Retinitis pigmentosa is a blinding eye disease that affects approximately 150,000 individuals in the US and 1.5 million people around the world. It is caused by the destruction of light-sensing… ...

UC Davis is conducting a clinical trial for in utero repair of myelomeningocele (MMC), the most severe form of spina bifida. MMC is a birth defect that occurs due to incomplete… Continue ReadingThe ...

Advancing Heart Health: CIRM Funds Tenaya Therapeutics’ Gene Therapy Trial for ARVC March 7, 2025 The California Institute for Regenerative Medicine (CIRM) recently announced funding a series of ...

Our candidate product PSCA-CAR_s15 uiNK is derived from transduction of iPSCs selected from the most ideal source and episomally reprogrammed from mature NK cells or CD34+ cells. Our goal is to ...

Meetings of the Grants Review Working Group will be held in a public session format except for the review of individual grant applications which will be conducted in closed session. THE ORDER OF ...

我们旨在阐明导致阿尔茨海默病 (AD) 的早期病因到后期缺陷的基因通路，这种疾病很常见且致命，且尚无有效的疾病改良药物 ...

Welcome to the frequently asked questions (FAQs) page of the California Institute for Regenerative Medicine (CIRM). Here, you’ll find answers to the most common questions you may have on CIRM. CIRM, ...

Through its strategic funding of clinical trials, CIRM helps advance innovative stem cell and gene therapy discoveries toward future treatments for patients. CIRM funds clinical trials across a broad ...

Jonathan Thomas, PhD, JD, is President and CEO of the California Institute for Regenerative Medicine (CIRM). Thomas was previously the Chair of the CIRM governing Board from June 2011 to March 2023.

CIRM is dedicated to bringing regenerative medicine treatments to patients who need them. This commitment begins with access to information. This page provides resources to learn more about ...